{
  "@context": {
    "biotools": "https://bio.tools/ontology/",
    "bsc": "http://bioschemas.org/",
    "bsct": "http://bioschemas.org/types/",
    "dct": "http://purl.org/dc/terms/",
    "edam": "http://edamontology.org/",
    "owl": "http://www.w3.org/2002/07/owl#",
    "rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
    "rdfs": "http://www.w3.org/2000/01/rdf-schema#",
    "sc": "http://schema.org/",
    "xsd": "http://www.w3.org/2001/XMLSchema#"
  },
  "@graph": [
    {
      "@id": "https://bio.tools/meet-uro",
      "@type": "sc:SoftwareApplication",
      "dct:conformsTo": "https://bioschemas.org/profiles/ComputationalTool/0.6-DRAFT",
      "sc:additionalType": "Web application",
      "sc:applicationSubCategory": [
        {
          "@id": "edam:topic_3384"
        },
        {
          "@id": "edam:topic_3360"
        },
        {
          "@id": "edam:topic_3379"
        },
        {
          "@id": "edam:topic_2229"
        }
      ],
      "sc:citation": [
        "pmcid:PMC8883304",
        {
          "@id": "https://doi.org/10.1177/17588359221079580"
        },
        "pubmed:35237353"
      ],
      "sc:description": "Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib.",
      "sc:isAccessibleForFree": true,
      "sc:license": "Not licensed",
      "sc:name": "Meet-URO",
      "sc:operatingSystem": [
        "Mac",
        "Linux",
        "Windows"
      ],
      "sc:url": "https://proviso.shinyapps.io/Meet-URO15_score/"
    },
    {
      "@id": "https://doi.org/10.1177/17588359221079580",
      "@type": "sc:CreativeWork"
    }
  ]
}